Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00083031
Status:
COMPLETED
Last Update Posted:
2019-05-21
First Post:
2004-05-14
Brief Title:
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
03-083
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Harold J Burstein MD PhD
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Genentech Inc | INDUSTRY |
| National Cancer Institute NCI | NIH |